Skip to main content
. 2020 Sep 30;10:549220. doi: 10.3389/fonc.2020.549220

Table 2.

Univariate analysis for overall survival.

Variables ALL (N = 160) HSPC (N = 52) CRPC(N = 108)
HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
Gleason sum score 0.248 0.454 0.284
  6–7 1 1 1
  8–10 1.30 (0.83–2.02) 1.50 (0.52–4.29) 1.31 (0.80–2.13)
Age 0.559 0.585 0.843
  ≤ 68 1 1 1
  >68 1.14 (0.74–1.74) 1.32 (0.49–3.57) 1.05 (0.65–1.68)
WHO performance status 0.003 0.196 0.037
  0 1 1 1
  1, 2 1.88 (1.24–2.86) 1.90 (0.72–4.99) 1.65 (1.03–2.63)
Cytoreductive extent <0.001 0.007 0.005
  Minor cytoreduction 1 Ref 1 Ref 1 Ref
  Major cytoreduction 0.46 (0.29–0.75) 0.002 0.18 (0.04–0.70) 0.014 0.55 (0.33–0.93) 0.025
  Total cytoreduction 0.25 (0.14–0.46) <0.001 0.18 (0.06–0.65) 0.009 0.29 (0.13–0.63) 0.002
Number of osseous metastases 0.002 0.127 0.063
  <5 1 1 1
  ≥5 2.13 (1.33–3.42) 2.21 (0.80–6.11) 1.72 (0.97–3.04)
Metastatic burden (CHAARTED) <0.001 0.034 0.005
  Low 1 1 1
  High 2.53 (1.62–3.96) 3.01 (1.09–8.35) 2.10 (1.25–3.53)
Risk classification (LATITUDE) 0.020 0.062 0.335
  Low-risk 1 1 1
  High-risk 1.64 (1.08–2.49) 2.73 (0.95–7.83) 1.26 (0.79–1.99)
Hormone sensitivity 0.006
  CRPC 1
  HSPC 0.47 (0.28–0.80)
PSA at radiotherapy initiation <0.001 0.043 0.059
  >16.5 ng/ml* 1 1 1
  ≤ 16.5 ng/ml 0.48 (0.32–0.72) 0.27 (0.07–0.96) 0.63 (0.39–1.02)
PSA response <0.001 0.052 0.002
  Decline ≤ 50% 1 1 1
  Decline > 50% 0.42 (0.27–0.64) 0.36 (0.13–1.01) 0.48 (0.30–0.77)

HSPC, hormone sensitive prostate cancer; CRPC, Castration-resistant prostate cancer; PSA, Prostate-specific antigen.

*

The optimal cutoff value of PSA at radiotherapy initiation defined by ROC curves. Bold values represent the p-values that are statistically significance.